Immuneering's Atebimetinib Shows Promising Results in Pancreatic Cancer
Immuneering Corporation (NASDAQ:IMRX) has made waves with its atebimetinib, showing promising results in a phase 2a study for first-line pancreatic cancer treatment. The drug achieved an 86% overall survival rate over nine months. Meanwhile, biotech stocks are in the spotlight, with analysts sharing their top picks.
Terry Chrisomalis, an analyst, favours Immuneering due to its novel MEK inhibitor, atebimetinib. The drug's combinability with various classes makes it a potential M&A target. Immuneering has also secured clinical trial collaborations with Regeneron Pharmaceuticals and Eli Lilly for lung cancer treatments.
On the other hand, ONeil Trader praises BridgeBio Pharma (NASDAQ:BBIO) despite recent share price appreciation. BridgeBio's broader pipeline and more advanced clinical-stage programs make it currently more attractive. The company expects positive data from at least two of its three late-stage trials by early 2026: encaleret and infigratinib. BridgeBio's Attruby, for treating ATTR cardiomyopathy, has also performed well in the U.S. market despite competition from Pfizer's Vyndaqel and Alnylam's Amvuttra.
Immuneering's atebimetinib shows great promise in pancreatic cancer treatment, making the company an attractive prospect. Meanwhile, BridgeBio Pharma's diverse pipeline and advanced clinical programs continue to impress analysts, with positive trial results expected in the near future.
